Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;4(Suppl 1):S73-7.
doi: 10.4103/0976-500X.120957.

Clinical and economic burden of adverse drug reactions

Janet Sultana  1 , Paola Cutroneo  1 , Gianluca Trifirò  1
Affiliations
Review

Clinical and economic burden of adverse drug reactions

Janet Sultana et al. J Pharmacol Pharmacother. 2013 Dec.

Abstract

Adverse drug reactions (ADRs) are unwanted drug effects that have considerable economic as well as clinical costs as they often lead to hospital admission, prolongation of hospital stay and emergency department visits. Randomized controlled trials (RCTs) are the main premarketing methods used to detect and quantify ADRs but these have several limitations, such as limited study sample size and limited heterogeneity due to the exclusion of the frailest patients. In addition, ADRs due to inappropriate medication use occur often in the real world of clinical practice but not in RCTs. Postmarketing drug safety monitoring through pharmacovigilance activities, including mining of spontaneous reporting and carrying out observational prospective cohort or retrospective database studies, allow longer follow-up periods of patients with a much wider range of characteristics, providing valuable means for ADR detection, quantification and where possible reduction, reducing healthcare costs in the process. Overall, pharmacovigilance is aimed at identifying drug safety signals as early as possible, thus minimizing potential clinical and economic consequences of ADRs. The goal of this review is to explore the epidemiology and the costs of ADRs in routine care.

Keywords: Adverse drug reactions; costs; pharmacovigilance; randomized controlled trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

References

    1. World Health Organization, The safety of medicines in public health programmes: Pharmacovigilance an essential tool. 2006. [Last accessed on 25 of June 2013]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharma... .
    1. Olsen S, Neale G, Schwab K, Psaila B, Patel T, Chapman EJ, et al. Hospital staff should use more than one method to detect adverse events and potential adverse events: Incident reporting, pharmacist surveillance and local real-time record review may all have a place. Qual Saf Health Care. 2007;16:40–4. - PMC - PubMed
    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ. 2004;329:15–9. - PMC - PubMed
    1. Aronson JK. Distinguishing hazards and harms, adverse drug effects and adverse drug reactions: Implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring. Drug Saf. 2013;36:147–53. - PubMed
    1. Martin K, Begaud B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004;57:86–92. - PMC - PubMed

LinkOut - more resources